vosaroxin
PreclinicalSmall molecule
vosaroxin is one of 29 small molecule programs targeting Acute Myeloid Leukemia (AML). It is currently in Preclinical.
1
Indications
8
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Acute Myeloid Leukemia (AML)
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 3
Cytosar
TevaPhase 3
Xospata
AstellasPhase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Komzifti
KKura Oncology, Inc.
Phase 3
Granulocyte Colony-Stimulating Factor
SanofiPhase 3
Lisaftoclax
Ascentage Pharma Group Inc.Phase 3
AG-120
Institut de Recherches Internationales ServierPhase 3
Mitoxantrone Hydrochloride Liposome
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia2 trials
Myelodysplastic Syndrome2 trials
Hematologic Malignancies1 trial
Myelodysplastic Syndromes1 trial
1 more indication
Acute Myeloid Leukemia (AML)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for vosaroxin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSunesis Pharmaceuticals